OncoMatch/Clinical Trials/NCT06645678
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Is NCT06645678 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Elranatamab and Mezigdomide for relapsed refractory multiple myeloma (rrmm).
Treatment: Elranatamab · Mezigdomide · Dexamethasone — The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
Subject must have received at least one proteasome inhibitor
Must have received: lenalidomide (lenalidomide)
Subject must have received at least one proteasome inhibitor and lenalidomide
Cannot have received: mezigdomide (mezigdomide)
Subject who has had prior treatment with mezigdomide
Cannot have received: anti-BCMA agent
Subject who has had prior treatment with anti-BCMA agents (including CAR T-cell therapy, bispecifics and antibodies)
Cannot have received: allogeneic stem cell transplantation
Exception: allowed if >1 year prior and no evidence of active GVHD
Subject has previously received allogeneic stem cell transplantation within a year during prior therapy
Cannot have received: autologous stem cell transplantation
Exception: allowed if >12 weeks prior
received autologous stem cell transplantation within 12 weeks of initiating study treatment
Lab requirements
Blood counts
Absolute neutrophil count (ANC) < 1,000/µL; Platelet count: < 75,000/µL for subjects in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count < 50,000/µL for subjects in whom ≥ 50% of bone marrow nucleated cells are plasma cells; Hemoglobin < 8 g/dL (< 4.9 mmol/L)
Kidney function
Estimated glomerular filtration rate (eGFR) < 30 mL/min or requiring dialysis
Liver function
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN); Serum total bilirubin > 1.5 × ULN, or for participants with documented Gilbert's syndrome > 3.0 mg/dL
Cardiac function
Impaired cardiovascular function or clinically significant cardiovascular diseases, defined as any of the following within 6 months prior to enrollment: acute myocardial infarction or acute coronary syndromes, clinically significant cardiac arrhythmias, thromboembolic or cerebrovascular events, prolonged QT syndrome (or QTcF > 470 msec at screening), LVEF <40%
Subject has any of the following laboratory abnormalities: ... ANC < 1,000/µL ... Platelet count ... Hemoglobin < 8 g/dL ... eGFR < 30 mL/min or requiring dialysis ... AST or ALT > 2.5 × ULN ... Serum total bilirubin > 1.5 × ULN ... Impaired cardiovascular function or clinically significant cardiovascular diseases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify